The Achievements for Oncotarget Continues

Oncotarget is a traditional journal that carries multiple disciplines. Its main focus is democratization.

Oncotarget celebrates democratization as its core values as it has Creative Commons Attribution 3.0 License.

Bearing in mind, there are other suggested studies that that Oncotarget has taken a focus towards besides just oncology: other topics of importance are gerotargeting, immunology, and other topics of interest.

Journals can be opened and explored more easily because of Oncotarget’s democratized nature.

This allows for breakthroughs from Oncotarget to treat cancer in a much, more expedient rate.

The end outcome of this goal is for Oncotarget to help the study of oncology proceed without much slowdown.

Through this, Oncotarget is listed in recognized scientific indexes.

Another benefit is that Oncotarget archives its published experiments each and every day.

This democratization of information allows Oncotarget for researchers to further their research much more expediently.

Has Oncotarget Accomplished Anything Currently?

Oncotarget has been involved with current achievements that need to be recognized.

One accomplishment feat that Oncotarget has currently is that they are able to increase their frequency of published articles from once a week to a twice-weekly schedule.

One particular achievement that Oncotarget is pleased in sharing is that Oncotarget researchers have been able to identify new therapeutic strategics to treat thyroid cancer.

In regards to their media presence, Oncotarget is actually working to engage with its listeners through its own podcast, Oncotarget. More on this topic will be discussed later in better detail.

Oncotarget still has remained indexed by most scientific databases such as Embase, BIOSIS Previews, Scopus, and Biological Abstracts. Learn more about Oncotarget at researchgate.net

Their accomplishments are not without merit

Achievements in The Media Platform

Oncotarget continues to proceed with their accomplishments in regards to their media platform objectives.

One notable achievement is that Oncotarget has been able to increase the frequency of their publication to avoid odd hiatuses or gaps in publication.

The following achievement is that Oncotarget has created its own podcast. The overall purpose of that podcast is to detail its findings in podcasting format.

The podcast is available on the following platforms such as Stitcher, Soundcloud, Player.FM, and iTunes. Follow Oncotarget journal on Twitter.

Understanding Democratization

Oncotarget is a free and open media space that allows for the open nature of research papers that to be easily shared among research.

This is a consequence of Oncotarget fairly understanding the importance of democratization.

Listen: https://itunes.apple.com/us/podcast/oncotarget/id1294363732?mt=2

Eric Lefkofsky Looks to Improve the Way Healthcare Professionals Have Access to Patient Information

Eric Lefkofsky is aiming to improve the treatment of cancer patients by giving researchers and clinicians easier and quicker access to resources that combines genomic information and therapeutic data. Lefkofsky is the co-founder and CEO of the startup company Tempus, which creates databases to help clinicians gather molecular date, clinical data, and therapeutic outcome response data into one source. The goal is to improve the free flow information between researchers, clinicians, nurses, and others so cancer patients can get the right health care treatment for their individual circumstances.

Lefkofsky is a graduate of the University of Michigan and the University of Michigan Law School. He is a Booth School of Business professor at the University of Chicago, but he is best known for being a serial entrepreneur who co-founded the global e commerce marketplace Groupon. Other companies Lefkofsky co-founded include Zest Health, Lightbank, Echo Global Logistics, and InnerWorkings. He is also a board member for several organizations, including World Business Chicago, the Art Institute of Chicago, Steppenwolf Theater Company, and Lurie Children’s Hospital.

In addition to his business ventures, Lefkofsky is a philanthropist who established Lefkofsky Family Foundation. He established this charitable foundation in 2006 with his wife Liz with the purpose of improving the quality of life for people in the communities the foundation serves. The foundation helps to provide people with access to a quality education, improve basic human rights, advance cancer research, and to expand artistic programs. The Lefkofsky Family Foundation is committed to caring for the well-being of others, eradicating cancer, and providing the city of Chicago with a strong cultural foundation in the following: http://www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html click here.

Lefkofsky was inspired to form Tempus after his wife’s breast cancer diagnosis. He noticed clinicians didn’t have readily available access to data on how certain treatments affect certain populations of cancer patients. He would like to have electronic medical records used in a way that combines all patient data so that clinicians can see the relationship between treatments and results.

Ultimately, Lefkofsky would like to see this process move beyond oncology research and be used on people who suffer from neurological disorders.